Effect of liraglutide on vascular inflammation evaluated by [64 cu]dotatate

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Effect of liraglutide on vascular inflammation evaluated by [64 cu]dotatate. / Zobel, Emilie H.; Ripa, Rasmus S.; von Scholten, Bernt J.; Curovic, Viktor Rotbain; Diaz, Lars Jorge; Hansen, Tine W.; Rossing, Peter; Kjaer, Andreas.

In: Diagnostics, Vol. 11, No. 8, 1431, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Zobel, EH, Ripa, RS, von Scholten, BJ, Curovic, VR, Diaz, LJ, Hansen, TW, Rossing, P & Kjaer, A 2021, 'Effect of liraglutide on vascular inflammation evaluated by [64 cu]dotatate', Diagnostics, vol. 11, no. 8, 1431. https://doi.org/10.3390/diagnostics11081431

APA

Zobel, E. H., Ripa, R. S., von Scholten, B. J., Curovic, V. R., Diaz, L. J., Hansen, T. W., Rossing, P., & Kjaer, A. (2021). Effect of liraglutide on vascular inflammation evaluated by [64 cu]dotatate. Diagnostics, 11(8), [1431]. https://doi.org/10.3390/diagnostics11081431

Vancouver

Zobel EH, Ripa RS, von Scholten BJ, Curovic VR, Diaz LJ, Hansen TW et al. Effect of liraglutide on vascular inflammation evaluated by [64 cu]dotatate. Diagnostics. 2021;11(8). 1431. https://doi.org/10.3390/diagnostics11081431

Author

Zobel, Emilie H. ; Ripa, Rasmus S. ; von Scholten, Bernt J. ; Curovic, Viktor Rotbain ; Diaz, Lars Jorge ; Hansen, Tine W. ; Rossing, Peter ; Kjaer, Andreas. / Effect of liraglutide on vascular inflammation evaluated by [64 cu]dotatate. In: Diagnostics. 2021 ; Vol. 11, No. 8.

Bibtex

@article{cefe877d0f6e4a40948c889b56683164,
title = "Effect of liraglutide on vascular inflammation evaluated by [64 cu]dotatate",
abstract = "Quantification of vascular inflammation before and after treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help reveal mechanistic pathways underlying the cardiovascular benefits of these drugs. We assessed change in vascular inflammation in the carotid arteries over 26 weeks by copper-64-labeled [1,4,7,10-tetraazacyclododecane-N,N{\textquoteright},N{\textquoteright}{\textquoteright},N{\textquoteright}{\textquoteright}{\textquoteright}-tetraacetic acid]-D-Phe1, Tyr3-octreotate ([64Cu]DOTATATE) PET in 30 participants included in a substudy of a double-blind trial where persons with type 2 diabetes (T2D) were randomized to liraglutide (n = 15) or placebo (n = 15) for 26 weeks. Mean age (SD) was 66.4 (7.2) years, HbA1c 56.4 (9.2) mmol/mol and BMI 28.9 (4.6) kg/m2. Weight and HbA1c were significantly reduced by liraglutide vs. placebo (p ≤ 0.01). The [64Cu]DOTATATE uptake (mean standardized uptake values) was significantly reduced in the liraglutide-treated group (−0.11 [95% confidence interval −0.19 to −0.03], p = 0.01) and not changed significantly in the placebo group (−0.07 [−0.14 to 0.01], p = 0.08). The mean difference between groups did not reach significance (−0.04 [−0.15 to 0.07], p = 0.44). In conclusion, [64Cu]DOTATATE uptake was reduced in persons with T2D treated with liraglutide. However, the reduction compared to placebo did not reach statistical significance, perhaps due to limited power. A reduction in vascular inflammation with liraglutide could help explain the cardiovascular protection observed with GLP-1 RAs in outcome studies but warrants further and larger studies.",
keywords = "GLP-1 RA, PET, Type 2 diabetes, Vascular inflammation",
author = "Zobel, {Emilie H.} and Ripa, {Rasmus S.} and {von Scholten}, {Bernt J.} and Curovic, {Viktor Rotbain} and Diaz, {Lars Jorge} and Hansen, {Tine W.} and Peter Rossing and Andreas Kjaer",
note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
doi = "10.3390/diagnostics11081431",
language = "English",
volume = "11",
journal = "Diagnostics",
issn = "2075-4418",
publisher = "MDPI AG",
number = "8",

}

RIS

TY - JOUR

T1 - Effect of liraglutide on vascular inflammation evaluated by [64 cu]dotatate

AU - Zobel, Emilie H.

AU - Ripa, Rasmus S.

AU - von Scholten, Bernt J.

AU - Curovic, Viktor Rotbain

AU - Diaz, Lars Jorge

AU - Hansen, Tine W.

AU - Rossing, Peter

AU - Kjaer, Andreas

N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021

Y1 - 2021

N2 - Quantification of vascular inflammation before and after treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help reveal mechanistic pathways underlying the cardiovascular benefits of these drugs. We assessed change in vascular inflammation in the carotid arteries over 26 weeks by copper-64-labeled [1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid]-D-Phe1, Tyr3-octreotate ([64Cu]DOTATATE) PET in 30 participants included in a substudy of a double-blind trial where persons with type 2 diabetes (T2D) were randomized to liraglutide (n = 15) or placebo (n = 15) for 26 weeks. Mean age (SD) was 66.4 (7.2) years, HbA1c 56.4 (9.2) mmol/mol and BMI 28.9 (4.6) kg/m2. Weight and HbA1c were significantly reduced by liraglutide vs. placebo (p ≤ 0.01). The [64Cu]DOTATATE uptake (mean standardized uptake values) was significantly reduced in the liraglutide-treated group (−0.11 [95% confidence interval −0.19 to −0.03], p = 0.01) and not changed significantly in the placebo group (−0.07 [−0.14 to 0.01], p = 0.08). The mean difference between groups did not reach significance (−0.04 [−0.15 to 0.07], p = 0.44). In conclusion, [64Cu]DOTATATE uptake was reduced in persons with T2D treated with liraglutide. However, the reduction compared to placebo did not reach statistical significance, perhaps due to limited power. A reduction in vascular inflammation with liraglutide could help explain the cardiovascular protection observed with GLP-1 RAs in outcome studies but warrants further and larger studies.

AB - Quantification of vascular inflammation before and after treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help reveal mechanistic pathways underlying the cardiovascular benefits of these drugs. We assessed change in vascular inflammation in the carotid arteries over 26 weeks by copper-64-labeled [1,4,7,10-tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid]-D-Phe1, Tyr3-octreotate ([64Cu]DOTATATE) PET in 30 participants included in a substudy of a double-blind trial where persons with type 2 diabetes (T2D) were randomized to liraglutide (n = 15) or placebo (n = 15) for 26 weeks. Mean age (SD) was 66.4 (7.2) years, HbA1c 56.4 (9.2) mmol/mol and BMI 28.9 (4.6) kg/m2. Weight and HbA1c were significantly reduced by liraglutide vs. placebo (p ≤ 0.01). The [64Cu]DOTATATE uptake (mean standardized uptake values) was significantly reduced in the liraglutide-treated group (−0.11 [95% confidence interval −0.19 to −0.03], p = 0.01) and not changed significantly in the placebo group (−0.07 [−0.14 to 0.01], p = 0.08). The mean difference between groups did not reach significance (−0.04 [−0.15 to 0.07], p = 0.44). In conclusion, [64Cu]DOTATATE uptake was reduced in persons with T2D treated with liraglutide. However, the reduction compared to placebo did not reach statistical significance, perhaps due to limited power. A reduction in vascular inflammation with liraglutide could help explain the cardiovascular protection observed with GLP-1 RAs in outcome studies but warrants further and larger studies.

KW - GLP-1 RA

KW - PET

KW - Type 2 diabetes

KW - Vascular inflammation

U2 - 10.3390/diagnostics11081431

DO - 10.3390/diagnostics11081431

M3 - Journal article

C2 - 34441365

AN - SCOPUS:85112466543

VL - 11

JO - Diagnostics

JF - Diagnostics

SN - 2075-4418

IS - 8

M1 - 1431

ER -

ID: 276850244